Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 25

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Item 8
Chunk 25
---
2024 and $380,182 of non -cash amortization of prepaid contracts in 2025 compared to no comparable
amortization in 2024. Additionally, the prior period included a non-cash loss on extinguishment of debt of $951,868 and a gain on
forgiveness of accrued compensation of $40,000, which did not recur in the current period. Changes in working capital also
contributed to the variance, primarily due to an increase in accounts payable and accrued expenses of $177,481 in 2025 compared to
$34,524 in 2024 and a decrease in accrued compensation in 2025 versus an increase in 2024.

Net
Cash Flows From Financing Activities:

Net
cash provided by financing activities during the six months ended June 30, 2025 was $0, as compared to net cash provided in financing
activities of $159,000 for the six months ended June 30, 2024. The decrease in net cash provided by financing activities was primarily
related to the absence of financing transactions in the current period, compared to proceeds from related-party notes payable of $109,000
and proceeds from the sale of common stock of $50,000 during the six months ended June 30, 2024.

Off-balance
sheet financing arrangements

We
have no obligations, assets or liabilities which would be considered off-balance sheet arrangements. We do not participate in transactions
that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which
would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance
sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased
any non-financial assets.

We have no off-balance sheet
arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Business
Development Activities

The
Company initiated business development activities in the Asian region in 2021. The Company has a strong strategic interest in accelerating
the drug development and potential commercialization efforts of JOTROL in this market. Our Chairman & CEO, presented in person, our
company’s status and pipeline at the BIOHK 2023 conference in Hong Kong in September of 2023. The